• Register
  • Login

European Journal of Molecular & Clinical Medicine

  • Home
  • Browse
    • Current Issue
    • By Issue
    • By Subject
    • Keyword Index
    • Author Index
    • Indexing Databases XML
  • Journal Info
    • About Journal
    • Aims and Scope
    • Editorial Board
    • Publication Ethics
    • Indexing and Abstracting
    • Peer Review Process
    • News
  • Guide for Authors
  • Submit Manuscript
  • Contact Us
Advanced Search

Notice

As part of Open Journals’ initiatives, we create website for scholarly open access journals. If you are responsible for this journal and would like to know more about how to use the editorial system, please visit our website at https://ejournalplus.com or
send us an email to info@ejournalplus.com

We will contact you soon

  1. Home
  2. Volume 8, Issue 4
  3. Author

Online ISSN: 2515-8260

Volume8, Issue4

Evaluation of Extended Sick Neonate Score (ESNS) to predict neurodevelopmental outcome at one year of age

    Dr. Aanchal Sachdeva, Dr. J Shrivastava, Dr. N Shrivastava, Dr. A Agrawal

European Journal of Molecular & Clinical Medicine, 2021, Volume 8, Issue 4, Pages 3067-3076

  • Show Article
  • Download
  • Cite
  • Statistics
  • Share

Abstract

Background: Various scoring systems are extensively applied in neonatal intensive care unit(NICU) to predict the immediate outcome of neonates and ESNS is one of those. None of the study in literature has used ESNS as long term predictor of morbidity in terms of neuro developmental outcome who survived in neonatal period.
Aims and Objectives:
Primary Objective:-. To determine immediate outcome of sick newborn using ESNS.
Secondary Objective:- To assess applicability of ESNS for predicting neuro developmental outcome at one year of age.
Methods: It was a hospital based prospective cohort study conducted over eighteen months in which 220 term neonates admitted were enrolled and the required parameters for ESNS were assessed. Immediate outcome was documented in terms of death, discharge and duration of stay. Neuro-developmental outcome between 12±3 months of age was assessed by The Bayley scales of infant and toddler development (Bayley – 4).
Results: Mortality rate was 48.2% in neonates with ESNS score <13 while only 1.5% in neonates with ESNS score of ≥13. The sensitivity for predicting immediate outcome was 75.8% and specificity of 95.2%. While to predict long term neuro-developmental impairment, 85% cases were developmentally delayed in ≥1 domain in ESNS <13 group while only 6.5% in ESNS ≥13 group. Cut off score of 13 had sensitivity of 95% and specificity of 88%(p <0.001).
Conclusion: ESNS can predict immediate outcome as well as long term neuro-developmental outcome with satisfactory sensitivity and specificity
Keywords:
    Extended sick neonate score (ESNS) neuro-developmental impairment neonatal mortality and morbidity Bayley 4 scale
  • PDF (416 K)
  • XML
(2022). Evaluation of Extended Sick Neonate Score (ESNS) to predict neurodevelopmental outcome at one year of age. European Journal of Molecular & Clinical Medicine, 8(4), 3067-3076.
Dr. Aanchal Sachdeva, Dr. J Shrivastava, Dr. N Shrivastava, Dr. A Agrawal. "Evaluation of Extended Sick Neonate Score (ESNS) to predict neurodevelopmental outcome at one year of age". European Journal of Molecular & Clinical Medicine, 8, 4, 2022, 3067-3076.
(2022). 'Evaluation of Extended Sick Neonate Score (ESNS) to predict neurodevelopmental outcome at one year of age', European Journal of Molecular & Clinical Medicine, 8(4), pp. 3067-3076.
Evaluation of Extended Sick Neonate Score (ESNS) to predict neurodevelopmental outcome at one year of age. European Journal of Molecular & Clinical Medicine, 2022; 8(4): 3067-3076.
  • RIS
  • EndNote
  • BibTeX
  • APA
  • MLA
  • Harvard
  • Vancouver
  • Article View: 61
  • PDF Download: 93
  • LinkedIn
  • Twitter
  • Facebook
  • Google
  • Telegram
Journal Information

Publisher:

Email:  editor.ejmcm21@gmail.com

  • Home
  • Glossary
  • News
  • Aims and Scope
  • Privacy Policy
  • Sitemap

 

For Special Issue Proposal : editor.ejmcm21@gmail.com

This journal is licensed under a Creative Commons Attribution 4.0 International (CC-BY 4.0)

Powered by eJournalPlus